Randomized trial develops transdermal patches of celecoxib, suggesting improved drug delivery and bioavailability.
The present study aimed to develop and evaluate Celecoxib-loaded transdermal drug delivery systems (TDDS) to overcome the limitations associated with oral administration of NSAIDs. Matrix-type transdermal patches were prepared using the solvent evaporation method with different polymeric combinations of HPMC E15, ethyl cellulose, and PVP K30. Preformulation studies revealed a melting point of 202–203°C, λmax at 234 nm, and excellent linearity (r² = 0.995). The calculated permeability coefficient and flux were found to be 4.4004 and 0.101 mg/cm²/hr, respectively, with a dose of 12.12 mg/10 cm²/12 hr. All formulations exhibited satisfactory physicochemical properties, including thickness (0.061–0.077 mm), drug content (89.16–95.04%), and folding endurance (99–125). In vitro diffusion studies showed a maximum drug release of 91.04% for formulation F1 over 12 hours, following the order F1 > F5 > F6 > F2 > F3 > F4. Release kinetics indicated non-Fickian diffusion with the optimized formulation best fitting the Higuchi model (r² = 0.9875). The study concludes that Celecoxib can be effectively formulated into transdermal patches to provide sustained drug release, improve bioavailability, and minimize systemic side effects.
No takes yet. Share an insight, caveat, or question.
Ms. Pratima Pathak1*, Dr. Anand Mahalwar2, Mr. Ashwanee Kumar Sahu3 (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: